Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305254 | 0.90 | SMN1; SMN2 (0.51) | HSD17B10SMN1; SMN2THRBGAAHTR3A | |
| SCHEMBL23411131 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2THRBGAALMNAMAPT | |
| SCHEMBL1121524 | 0.84 | ALDH1A1 (0.49) | MAPTPARP1MMP13GPR119 | |
| SCHEMBL1005073 | 0.82 | PARP1 (0.44) | SMN1; SMN2GAAHTR3AKCNH2LMNA | |
| SCHEMBL23411442 | 0.82 | MAPT (0.49) | SMN1; SMN2THRBGAALMNAMAPT | |
| SCHEMBL1005912 | 0.80 | TOP2A (0.40) | HSD17B10HTR3AKCNH2PARP1TOP2A | |
| SCHEMBL4308323 | 0.79 | TOP2A (0.51) | HSD17B10SMN1; SMN2HTR3AKCNH2LMNA | |
| SCHEMBL26651033 | 0.78 | EED (0.45) | HSD17B10SMN1; SMN2THRBGAALMNA | |
| SCHEMBL1004889 | 0.78 | TOP2A (0.42) | HTR3APARP1TOP2A | |
| SCHEMBL1004469 | 0.77 | HTR3A (0.48) | HTR3AKCNH2PARP1TOP2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278301-B2 | 2-alkylbenzoxazole carboxamides as 5HT3 modulators | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090227576-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-7553846-B2 | 2-alkylbenzoxazole carboxamides as 5-HT3 modulators | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20080214601-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | AMR TECHNOLOGY, INC. (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227576-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | HSD17B10 3418/4885SMN1; SMN2 2978/4885THRB 855/4885 |
| US-20080214601-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | HSD17B10 3418/4885SMN1; SMN2 2978/4885THRB 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.